Trials / Completed
CompletedNCT00544154
Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis
Efficacy and Safety of CDP870 400 mg in Combination With Methotrexate Compared to Methotrexate Alone in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Are Partial Responders to Methotrexate
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 247 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study was to determine the efficacy of CDP870 in treating RA signs/symptoms in patients who were partial responders to MTX. Other purposes were to show additional efficacy without increased toxicity and the immunogenic response to CDP870 during combined CDP870 and MTX therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDP870 |
Timeline
- Start date
- 2002-10-01
- Primary completion
- 2004-01-01
- Completion
- 2004-01-01
- First posted
- 2007-10-16
- Last updated
- 2013-09-04
Source: ClinicalTrials.gov record NCT00544154. Inclusion in this directory is not an endorsement.